Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half
Newsfile Corp•13/08/2026•12:06 ET
0
Whiz Insights
Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission.
To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/309500_adiaimage.jpg
Get started
Create a free account to read the full story.